T cells come to the rescue as studies show they buck omicron

New study suggests , T cells could lead , to universal COVID vaccine.Newsweek reports that a new study suggests that immune system T cells from previous illnesses could help defend people against COVID-19. .The research could lead to a new generation of potential vaccines. .The study was conducted at the Imperial College London under lead author Dr. Rhia Kundu. .Another senior author of the study, professor Ajit Lalvani, said that a new type of vaccine using T cells could prevent infection from current and future variants of COVID. .Our study provides the clearest evidence to date that T cells induced by common cold coronaviruses play a protective role against SARS-CoV-2 infection, Professor Ajit Lalvani, director of the NIHR Respiratory Infections Health Protection Research Unit at Imperial College London, via BBC.However, Kundu and others have cautioned that while the study showed promising results, people should still get vaccinated now.While this is an important discovery, it is only one form of protection, and I would stress that no one should rely on this alone. Instead, the best way to protect yourself against COVID-19 is to be fully vaccinated, including getting your booster dose, Dr. Rhia Kundu, Imperial College London press release, via BBC.Newsweek explains that T cells are a form of white blood cells and are a critical part of the immune system. .T cells reportedly provide protection by attacking proteins within the COVID-19 virus. .The journal, Nature Communications published the study, on Jan. 10

An unsung arm of the immune system appears to protect against severe disease with the omicron variant even when antibodies wane, helping to explain why a record wave of infections hasn’t engulfed hospitals so far.

T cells, the body’s weapon against virus-infected cells, were primed enough by vaccination that they defended against omicron in separate studies from Erasmus University in the Netherlands and the University of Cape Town in South Africa.

The findings could help explain why the wave of omicron cases hasn’t so far caused a surge in mortality from South Africa to the U.S. and the U.K. Unlike antibodies, T cells can target the whole of the virus’s spike protein, which remains largely similar even in the highly mutated omicron.

The Dutch researchers looked at 60 vaccinated health care workers and found that while their antibody responses to omicron were lower or nonexistent compared with the beta and delta variants, T cell responses were largely unaltered, “potentially balancing the lack of neutralizing antibodies in preventing or limiting severe Covid-19.”

The study from the University of Cape Town’s Institute of Infectious Disease and Molecular Medicine looked at patients who had recovered from Covid or been vaccinated with shots from Pfizer Inc. and partner BioNTech SE or Johnson & Johnson. They found that 70% to 80% of the T cell responses they assessed held up against omicron.

Recent weeks have brought evidence that the new strain can erode vaccine protection, prompting governments to push for booster shots to raise the level of antibodies that can fight off the variant.

But immune protection has several layers. While antibodies block infection, T cells kill infected cells, preventing the virus from spreading and causing worse disease, Wendy Burgens, one of the University of Cape Town study authors, wrote on her Twitter account Virus Monologues.

“They can’t prevent you from getting infected, but they can minimize the damage that comes afterwards,” she said.

T cells are white blood cells that can remember past diseases, kill virus-infected cells and rouse antibodies to marshal defenses. People infected with another coronavirus that was responsible for the SARS outbreak in 2003, for example, were found to still have a T-cell response to the disease 17 years later.

Another study found booster shots increased the production of T cells in the face of an omicron infection. Giving J&J’s vaccine to people who had previously received a messenger RNA shot yielded better results, though a third dose of Pfizer and BioNTech’s immunization also led to higher levels of cellular immunity and neutralizing antibodies after one month, according to findings from Beth Israel Deaconess Medical Center.

For more content like this, sign up for the Pulse newsletter here.